The Orchestration Gap

A Mandate Without a Mechanism

The National Plan to End Parkinson’s Act, passed with bipartisan support in 2024, created the National Parkinson’s Project and placed MJFF at the center of its implementation. It also imposed the first statutory congressional reporting deadline in MJFF’s history — and that deadline, January 2, 2026, was missed. The failure was not MJFF’s. Despite open nominations closing in March 2025 and relentless advocacy from the foundation and its partners, the Department of Health and Human Services did not seat the Advisory Council until April 10, 2026 — over a year late. Legislative approval produced no coordinated delivery mechanism, and a compressed execution window has now replaced a missed one.

That delay is a symptom of the underlying structural condition. MJFF is responsible for synchronizing the Department of Health and Human Services, the National Institutes of Health, NINDS, the EPA, state-level implementation actors, patient advocacy organizations, and competing disease communities — in service of a mandate that covers not just Parkinson’s disease but atypical parkinsonisms including PSP, CBD, and MSA. MJFF drove the resolution. No single organization, including MJFF, controls that system. And the system still has no standing mechanism for making binding decisions across it at pace.

At the same moment, MJFF’s core scientific mandate has undergone a hard pivot. The May 2026 rebranding of the Parkinson’s Progression Markers Initiative to the Parkinson’s Precision Medicine Initiative is not a marketing update. It reflects a fundamental realization that Parkinson’s disease is heterogeneous — multiple subtypes, driven by distinct underlying biologies, requiring biologically defined patient cohorts rather than generic recruitment. The alpha-synuclein seed amplification assay, validated on PPMI samples, detects the disease in 93.3% of sporadic Parkinson’s patients and 95.9% of GBA mutation carriers — but in only 67.5% of LRRK2 mutation carriers overall, and in just 34.7% of LRRK2 carriers who do not exhibit olfactory deficits. That divergence means the assay that unlocked precision medicine simultaneously proved that no single biomarker can qualify patients across the full disease spectrum. Clinical trial design has become exponentially more complex at the exact moment MJFF is scaling its research network to 32 new international teams.

The Infrastructure That Doesn’t Yet Exist

The April 2026 expansion of the Collaborative Research Network, announced jointly with Aligning Science Across Parkinson’s, commits $261 million to fund 32 new teams across 187 institutions in 24 countries. The stated ambition is a standardized, open-access global toolkit of research resources. The operational reality is that nearly 400 highly competitive investigators, governed by different university legal frameworks, operating under different data privacy regimes, and incentivized by publication priority rather than interoperability, must now agree on shared rules for how data, tools, intellectual property, and biological materials move across institutions. Those rules do not yet exist. Without them, the network produces parallel silos rather than cumulative science.

The same fragmentation risk runs through MJFF’s precision medicine data infrastructure. The LITE program — governed by an MJFF steering committee, implemented by the University of Dundee, feeding into the Global Parkinson’s Genetics Program and the Accelerating Medicine Partnership — requires seamless handoffs between clinical sites, corporate partners like Metabolon, academic implementers, and open-access federal platforms. Each handoff is a point of ontological misalignment, privacy friction, or IP ambiguity. If those handoffs aren’t forced into alignment by a deliberate process, the multi-million dollar data architecture degrades into isolated lakes that cannot communicate.

Finally, the late-May 2026 failure of the Phase 2b LUMA trial for the LRRK2 inhibitor BIIB122 — co-developed by Biogen and Denali Therapeutics — surfaces the clinical pipeline risk that runs beneath all of this. LUMA enrolled 648 patients and ran for up to 144 weeks. The drug achieved over 90% peripheral LRRK2 kinase inhibition and a 30% reduction in a downstream biomarker of LRRK2 activity. It failed to slow disease progression on a single endpoint. The program has now been discontinued for idiopathic Parkinson’s disease; only the Phase 2a BEACON study, restricted to confirmed LRRK2 mutation carriers, continues. As Chief Mission Officer Todd Sherer noted publicly, each failure advances the field’s understanding of Parkinson’s biology — and that is precisely the point. When commercial partners exhaust their tolerance for biological complexity, the burden of de-risking the targets returns to MJFF. No standing mechanism currently exists to reconvene the right stakeholders, reset shared assumptions, and build a committed path forward.

Why Conventional Approaches Won’t Close the Gap

Why Process Is the Variable That Matters

Each of these challenges shares not just a structural root cause, but a structural solution. The orchestration gap is not solved by more funding, more analysis, or more stakeholder meetings run one at a time. It is solved by a process that brings the right actors into the same room, with the right framing, and produces a committed decision — not a report, not a set of recommendations, not another advisory output that requires a second round of internal approval before anything moves.

When the stakes are high, most organizations do what makes sense: they commission expert working groups, convene task forces, and build rigorous analytical cases. The research on this is unambiguous: how you decide matters more than what you analyze.

The implication for an organization navigating MJFF’s current operating environment is direct: more data will not produce inter-agency alignment. More task forces will not build open-science compliance across 400 competitive investigators. A deliberately designed process — one that brings the right actors into the same room, with the right framing, at the right moment — is what converts strategic clarity into committed action.

Eight Challenges. One Structural Root Cause.

Each of the following challenges was identified through MMG’s independent research as a file where the primary execution barrier is structural — not scientific, not financial, and not a function of MJFF’s internal capability. In each case, the actors who must move hold conflicting incentives, and no standing forum exists to produce a binding commitment across them.

What Structured Convening Delivers

A Mind Meeting is an intensive 3-day solving sprint designed specifically for challenges where progress depends on the simultaneous commitment of actors who sit outside any single organization’s authority. It is not an advisory board, a conference, or a strategic planning retreat in the conventional sense. It is built around a specific challenge — one where the actors who must move hold conflicting incentives, where no standing forum exists to produce a binding outcome, and where standard execution tools have already reached their limits. For MJFF, every challenge on this page meets that description.

The preparation phase identifies which actors must be in the room, how the challenge must be framed to make productive deliberation possible, and what decisions need to emerge by the end of the session. MMG facilitates the session itself — managing the dynamics that cause multi-stakeholder deliberations to collapse into consensus theater rather than committed decisions — and structures the follow-through that translates outcomes into accountable next steps. Who gets invited, and in what role, is determined by a single criterion: who controls the part of the path that everyone else is waiting on.

What a client organization leaves with is specific: a committed decision, a clear allocation of responsibility across actors, and a defined condition for reconvening if the environment changes. No open questions that reset the conversation. No advisory outputs that require a second round of internal approval before anything moves. For MJFF, where execution delays translate directly into missed congressional deadlines, fractured open-science networks, and clinical pipelines that lose partner confidence, that specificity is not a feature of the process. It is the purpose of it.

Depending on the specific challenge and where key actors are located, Mind Meeting workshops are designed to be held in-person, virtually, or in a hybrid format. For challenges where the quality of deliberation depends on the dynamics of a shared physical room — inter-agency alignment sessions, coalition governance negotiations, or working sessions with significant relationship friction — we recommend an in-person format. For challenges where geographic distribution of stakeholders is the binding constraint, a structured virtual session can achieve the same decision-grade outcomes. The format is a design decision, not a default.

How MMG Compares

Book a Discovery Call

More analysis will not seat a functioning inter-agency operating model for the National Parkinson’s Project. More task forces will not produce open-science compliance across 400 competitive investigators who have never been in the same room. What converts a mandate — federal, scientific, or organizational — into committed, coordinated action is a deliberately designed process that brings the right actors together, forces the real trade-offs, and produces decisions with named owners.

That is what Mind Meeting Group builds. To learn more, book a discovery call with Mark McCarvill at the link below.